Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
1999-07-26
2001-02-20
Krass, Frederick (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S213010, C514S217110, C514S299000, C514S307000, C514S330000
Reexamination Certificate
active
06191144
ABSTRACT:
FIELD OF THE INVENTION
The present invention is directed to the use of a group of ACE inhibitors to stimulate angiogenesis in mammals or in mammalian tissue in vitro. Specifically, the present invention is directed to inducing or enhancing angiogenesis through the administration of a group of ACE inhibitors and to ACE inhibitor-containing compositions for effecting the inducement or enhancement of angiogenesis. The ACE inhibitors may also be useful in the promotion of angiogenesis, such as in the promotion of wound healing, bone healing, and in the treatment of bums, as well as in promoting the formation, maintenance, and repair of tissue. In a preferred embodiment, the ACE inhibitor, quinapril, or quinaprilat, is used to treat, prophalactically or otherwise, mammals in need of angiogenic treatment.
BACKGROUND OF THE INVENTION
Angiogenesis refers to the growth of new blood vessels, or “neovascularization,” and involves the growth of capillaries composed of endothelial cells. Angiogenesis is an integral part of many important biological processes, and may aid in the healing of wounds and fractures, the vascularizing of synthetic skin grafts, and the enhancement of collateral circulation where there has been vascular occlusion or stenosis. New blood vessel formation is required for the development of any new tissue, whether normal or pathological, and thus represents a potential control point in regulating many disease states, as well as a therapeutic opportunity for encouragement of the growth of normal tissue.
The complete process of angiogenesis is not entirely understood, but it is known to involve the endothelial cells of the capillaries. Endothelial cells line the walls of blood vessels, and capillaries are comprised almost entirely of endothelial cells. The angiogenic process comprises a cascade of events, including protease secretion by endothelial cells, degradation of the basement membrane, migration through the surrounding matrix, proliferation, alignment, differentiation into tube-like structures, and synthesis of a new basement membrane.
A number of factors are well-known in the art to stimulate angiogenesis. Many of these are peptide factors, and the most notable among these are fibroblast growth factors, epidermal growth factors, vascular endothelial growth factors, insulin-like growth factors, transforming growth factors, platelet-derived growth factor, and interleukins. Other factors which are known to show angiogenic-stimulating activity, but which are not proteins, include prostaglandins E1 and E2, fragments of hyaluronic acid and nicctinamine. However, the therapeutic applicability of some of these compounds, especially as systemic agents, is limited by their potent pleiotropic effects on various cell types. There remains a need, therefore, for an angiogenic agent with more general applicability.
REFERENCES:
patent: 4344949 (1982-08-01), Hoefle et al.
patent: 4374829 (1983-02-01), Harris et al.
patent: 4425355 (1984-01-01), Hoefle et al.
patent: 5166143 (1992-11-01), Ondetti et al.
patent: 5231080 (1993-07-01), Scholkens
Takeshita S., et al., “Therapeutic Angiogenesis A Single Intraarterial Bolus of Vascular Endothelial Growth Factor Augments Revascularization in a Rabbit Ischemic Hind Limb Model”,J. Clin. Invest., vol. 93, Feb. 1994, pp 662-670.
Fabre J., et al., “Angiotensin Converting Enzyme Inhibition With Quinaprilate Stimulates Angiogenesis in a Rabbit Model of Hindlimb Ischemia”,Am. J. Cardiol., vol. 31, No. 2, Feb. 1998, p 239A.
J. M. Isner, “Angiogenesis for Revascularization of Ischaemic Tissues”,Eur. Heart J., vol. 18, Jan. 1997, pp 1-2.
Stoll M., et al., “The Angiotensin AT2-Receptor Mediates Inhibition of Cell Proliferation in Coronary Endothelial Cells”,J. Clin. Invest., vol. 95, Feb. 1995, pp 651-657.
Mancini G. B., et al., “Angiotensin-Converting Enzyme Inhibition With Quinapril Improves Endothelial Vasomotor Dysfunction in Patients With Coronary Artery Disease”,Circulation, vol. 94, 1996 pp 258-265.
Rakugi H., et al., “Vascular Injury Induces Angiotensinogen Gene Expression in the Media and Neointima”,Circulation, vol. 87, No. 1, Jan. 1993, pp 283-290.
Naftilan A. J., et al., “Localization and Differential Regulation of Angiotensinogen mRNA Expression in the Vessel Wall”,J. Clin. Invest., vol. 87, Apr. 1991, pp 1300-1311.
Caldwell P., et al., “Angiotensin-Converting Enzyme: Vascular Endothelial Localization”,Science, vol. 191, Mar. 12, 1976, pp 1050-1051.
VanLeeuwen R., et al., “Angiotensin II Increases Plasminogen Activator Inhibitor Type 1 and Tissue-Type Plasminogen Activator Messenger RNA in Cultured Rat Aortic Smooth Muscle Cells”,Circulation, vol. 90, No. 1, Jul. 1994, pp 362-368.
Diet F., et al., “Increased Accumulation of Tissue ACE in Human Atherosclerotic Coronary Artery Disease”,Circulation, vol. 94, 1996, pp 2756-2767.
Victor J. Dzau, “Molecular and Physiological Aspects of Tissue Renin-Angiotensin System: Emphasis on Cardiovascular Control”,J. Hypertens., vol. 6, No. 3, 1988, pp S7-S12.
Peters K., et al., “Vasopressin and the Mature Coronary Collateral Circulation”,Circulation, vol. 79, No. 6, Jun. 1989, pp 1324-1331.
Yang H. T., et al., “Angiotensin-Converting Enzyme Inhibition Increases Collateral-Dependent Muscle Blood Flow”,J. Appl. Physiol., vol. 75, 1993, pp 452-457.
Ziada A., et al., “The Effect of Long-Term Vasodilation on Capillary Growth and Performance in Rabbit Heart and Skeletal Muscle”,Cardiovascular Research, vol. 18, 1984, pp 724-732.
Andrade S. P., et al., “Inhibitors of Nitric Oxide Synthase Selectively Reduce Flow in Tumor-Associated Neovasculature”,Br. J. Pharmacol, vol. 107, 1992, pp 1092-1095.
Ziche M., et al., “Nitric Oxide Mediates Angiogenesis In Vivo and Endothelial Cell Growth and Migration In Vitro Promoted by Substance P”,J. Clin. Invest., vol. 94, Nov. 1994, pp 2036-2044.
Munzenmaier D. H., et al., “Opposing Actions of Angiotensin II on Microvascular Growth and Arterial Blood Pressure”,Hypertension, vol. 27, 1996, pp 760-765.
Le Noble F. A., et al., “Evidence for a Novel Angiotensin II Receptor Involved in Angiogenesis in Chick Embryo Chorioallantoic Membrane”,Am. J. Physiol., vol. 264, 1993, pp R460-R465.
Cameron N. E., et al., “angiotensin Converting Enzyme Inhibition Prevents Development of Muscle and Nerve Dysfunction and Stimulates Angiogensis in Streptozotocin-Diabetic Rats”,Diabetologia, vol. 35, 1992, pp 12-18.
Maxfield E. K., et al., “Angiotensin II Receptor Blockade and Nerve Function, Modulates Nerve Blood Flow and Stimulates Endoneurial Angiogenesis in Streptozotocin-Diabetic Ratsand Nerve Function”,Diabetologia, vol. 36,1993, pp 1230-1237.
Olivetti G., et al., “Spirapril Prevents Left Ventricular Hypertrophy, Decreases Myocardial Damage and Promotes Angiogenesis in Spontaneously Hypertensive Rats”,J. Cardiovasc, Pharmacol., vol. 21, No. 3, 1993, pp 362-370.
Clozel J. P., et al., “Effects of Chronic ACE Inhibition on Cardiac Hypertrophy and Coronary Vascular Reserve in Spontaneously Hypertensive Rats With Developed Hypertension”,J. Hypertens., vol. 7, 1989, pp 267-275.
Gohlke P., et al., “Blockade of Bradykinin B2Receptors Prevents the Increase in Capillary Density Induced by Chronic Angiotensin-Converting Enzyme Inhibitor Treatment in Stroke-Prone Spontaneously Hypertensive Rats”,Hypertension, vol. 29, No. 1, Jan. 1997, pp 478-482.
O'Driscoll G., et al., “Improvement in Endothelial Function by Angiotensin Converting Enzyme Inhibition in Insulin-dependent Diabetes Mellitus”,J. Clin. Invest., vol. 100, No. 3, Aug. 1997, pp 678-684.
Fabris B., et al., “Inhibition of Angiotensin-Converting Enzyme (ACE) in Plasma and Tissue”,J. Cardiovasc. Pharmacol., vol. 15, Suppl. 2, 1990, pp S6-S13.
Prens E., et al., “Nephrotic Syndrome in Patient on Captopril”,Lancet, vol. 2, Aug. 1979, pp 306-307.
Gavras I., et al., “Fatal Pancytopenia Associated with the Use of Captopril,”Ann. Intern. Med., vol. 94, No. 1, Jan. 1981, pp 58-59.
Volpert O., et al, “Captopril Inhibits Angiogenesis and Slows the Growth of Experimental Tumores in Rats”,J. Clin. Invest., vol. 98, No. 3, Aug. 1996, pp 671-679.
William
Aktins Michael J.
Krass Frederick
Warner-Lambert & Company
LandOfFree
Method of using angiotensin converting enzyme inhibitor to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of using angiotensin converting enzyme inhibitor to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of using angiotensin converting enzyme inhibitor to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2578940